Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Adcentrx Therapeutics, Inc.Startup |
Active Organization Adcentrx Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H62N6O5S |
InChIKeyVNKVPXRCRUDPAH-JYZGKHMWSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | Adcentrx Therapeutics, Inc.Startup | 17 Apr 2024 |